PHISOHEX Drug Patent Profile
✉ Email this page to a colleague
When do Phisohex patents expire, and what generic alternatives are available?
Phisohex is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in PHISOHEX is hexachlorophene. There are seven drug master file entries for this compound. Additional details are available on the hexachlorophene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PHISOHEX?
- What are the global sales for PHISOHEX?
- What is Average Wholesale Price for PHISOHEX?
Summary for PHISOHEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,287 |
| DailyMed Link: | PHISOHEX at DailyMed |
Recent Clinical Trials for PHISOHEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Natividad Medical Center | N/A |
US Patents and Regulatory Information for PHISOHEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PHISOHEX | hexachlorophene | EMULSION;TOPICAL | 006882-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | PHISOHEX | hexachlorophene | EMULSION;TOPICAL | 008402-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
